Katrin Sproesser

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

James Tsai, John Tayu Lee, Weiru Wang et al. · Proceedings of the National Academy of Sciences · 2008 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Sydney M. Shaffer, Margaret C. Dunagin, Stefan Torborg et al. · Nature · 2017 · 1.3K citations

Medicine, Cancer Biology, Oncology +16

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Gao Zhang, Dennie T. Frederick, Lawrence W. Wu et al. · Journal of Clinical Investigation · 2016 · 299 citations · Full text

Life Sciences, Cancer Biology, Oncology +16

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

Nikolas K. Haass, Katrin Sproesser, Thiennga K. Nguyen et al. · Clinical Cancer Research · 2008 · 242 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler et al. · Cell Reports · 2013 · 181 citations · Full text

Medicine, Genetics, Oncology +16